Efficacy and Safety of an Indian Bevacizumab BIOSimilar (BEVATAS) for Treatment-Naïve Diabetic Macular Edema (BIOS-DME Study)
Somnath Chakraborty, Jay U Sheth, Santanu Ganguly, Preesha Reddy · 2026
Read Efficacy and Safety of an Indian Bevacizumab BIOSimilar (BEVATAS) for Treatment-Naïve Diabetic Macular Edema (BIOS-DME Study) by Somnath Chakraborty, Jay U Sheth, Santanu Ganguly, Preesha Reddy (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13264999.txt.
Description
Somnath Chakraborty and colleagues published a 2026 real-world study of an Indian biosimilar eye drug for diabetic macular edema, swelling at the center of the retina that blurs sight. The drug, Bevatas, copies bevacizumab, which blocks vessel growth signals. Cost limits care in India, so a cheaper copy matters if it works and is safe.
The study followed 123 eyes treated from 2022 to 2025 with three loading injections, then as-needed dosing. At twelve months, vision had improved clearly and central retinal thickness had fallen from about 470 to about 197 micrometres. A marker of inflammation present in 35.8 percent of eyes cleared by month one. Eyes needed an average of 4.6 injections, and over half also got laser treatment. No significant eye or body side effects were noted.
Catalog record
| CREATOR | Somnath Chakraborty, Jay U Sheth, Santanu Ganguly, Preesha Reddy |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 29556 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |